CELLULAR GOODS PLC — Regulatory Filings 2021

Dec 1, 2021

National Storage Mechanism | Additional information

RNS Number : 0878U

Cellular Goods PLC

01 December 2021

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press release

1 December 2021

Cellular Goods PLC

("Cellular Goods" or "the Company")

Launch of inaugural product range and ecommerce platform

Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products formulated with lab-made cannabinoids, is pleased to announce the launch today of its inaugural product ranges and ecommerce platform, found at cellulargoods.co.

The launch comprises two product ranges and comes just nine months after the start-up of the Company's commercial operations following its flotation on the London Stock Exchange.

The inaugural range comprises the UK's first premium CBG (cannabigerol) skincare offering including a serum, a face-oil and an after-shaving moisturiser. The products contain ultra-pure, biosynthetic CBG, which has demonstrated anti-inflammatory, anti-oxidant and anti-bacterial properties. All three products have been through an extensive testing process and are fully validated for marketing and labelling as suitable for sensitive skin, dermatologically tested and dermatologist approved.

The second range is a clinically validated CBD (cannabidiol) ingestibles range. This range complies with novel food regulations in both the UK and the EU and is certified under Good Manufacturing Practice (GMP) standards. The ingestibles range comprises a tincture, a spray and capsules, covering the most popular methods of consumption. These have been extensively tested to ensure safety, stability and quality. Both product ranges do not require the cultivation of the cannabis sativa plant, and contain 0% THC, the psychoactive component of cannabis sativa.

In addition, the Company's new ecommerce platform has gone live, enabling customers in the UK to place online purchase orders for five of the six products as of today. The skincare serum will go on sale from February 2022 due to supply constraints at the Company's manufacturing partner until early in the new year.

Alexis Abraham, Chief Executive of Cellular Goods, commented: "Today is a major milestone for the Company with the launch of the UK's first CBG skincare products on a best-in-class ecommerce platform. Leading with CBG sets us apart from the competition, and to also be able to offer consumers CBD ingestibles at the same time delivers on our vision to become the first true cannabinoid company. We have taken less than a year from a standing start to put Cellular Goods at the forefront of the cannabinoid and wellness industries, and as of today, we have started a new chapter in our growth by entering a revenue-generating phase. Consumers are now familiar with CBD, and we believe there is a substantial and growing demand for a more innovative and premium brand offering clean, green, and compliant products and look forward to delivering on our potential".

For further information please contact:

Cellular Goods
Alexis Abraham Chief Executive Neil Thapar Investor Relations	+44 207 031 6871 +44 787 645 5323
Tennyson Securities
Corporate Broker Peter Krens	+44 207 186 9030
Novum Securities
Corporate Broker Colin Rowbury Jon Belliss	+44 207 399 9427
Tancredi Intelligent Communication
Media Relations Helen Humphrey Edward Daly Fabio Galloni Roversi Monaco Charlie Hobbs Salamander Davoudi cellulargoods@tancredigroup.com	+44 744 922 6720 +44 786 143 0057 +44 788 867 2701 +44 789 755 7112 +44 795 754 9906

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDDZMFMKGRGMZM